secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0000950170-24-129507
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics regains Nasdaq compliance, hearing cancelled
----------------------------------------------------------------

- Nasdaq confirmed Iterum cured its Listing Rule 5550(b) deficiency; previously scheduled Nov 21 hearing cancelled.
- Company will continue trading on Nasdaq Capital Market; avoids potential delisting.
- CEO Corey Fishman expressed commitment to adhere to listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024129507/0000950170-24-129507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024129507/itrm-20241120.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer